An opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Hydrocodone | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Magnesium sulfate | The therapeutic efficacy of Dextromoramide can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dextromoramide may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Orphenadrine | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Pramipexole | Dextromoramide may increase the sedative activities of Pramipexole. |
| Ropinirole | Dextromoramide may increase the sedative activities of Ropinirole. |
| Rotigotine | Dextromoramide may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dextromoramide. |
| Sodium oxybate | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Thalidomide | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Dextromoramide is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Dextromoramide. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Dextromoramide. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextromoramide. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Dextromoramide. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Dextromoramide. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dextromoramide. |
| Naltrexone | The therapeutic efficacy of Dextromoramide can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Dextromoramide. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Dextromoramide. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dextromoramide. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Dextromoramide. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dextromoramide. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dextromoramide. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Dextromoramide. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Dextromoramide. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dextromoramide. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with Dextromoramide. |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with Dextromoramide. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dextromoramide. |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Dextromoramide is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Dextromoramide can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Naloxegol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dextromoramide. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dextromoramide. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dextromoramide. |
| Mirtazapine | Dextromoramide may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Dextromoramide. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Alaproclate. |
| Ethanol | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide. |
| Phentermine | Phentermine may increase the analgesic activities of Dextromoramide. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Dextromoramide. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Dextromoramide. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Dextromoramide. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Dextromoramide. |
| MMDA | MMDA may increase the analgesic activities of Dextromoramide. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Dextromoramide. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dextromoramide. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextromoramide. |